Revvity, Inc. · NYSE:RVTY
Revvity — Q2 2025 Earnings Presentation
9 slides from Revvity's earnings presentation, Jul 28, 2025
Slide 1: Second Quarter 2025 Earnings
Second Quarter 2025 Earnings July 28, 2025
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Market Performance Launched IDS i20 ChLIA Stability across Life Sciences & Newborn diagnostic analyzer Pharma/Biotech & Academic driving solid overall growth Unveiled Signals One Strong Diagnostic trends in EPS above expectations with software platform U.S. & EU offset weake
Slide 4: 2Q25 Revenue Highlights
2Q25 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring -MSD -MSD +LSD $0.7 B +MSD +MSD $0.7 B +MSD $0.7 B +MSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our w
Slide 5: 2Q25 Financial Results
2Q25 Financial Results REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $720M 26.6% $1.18 $115M +4% y/y -210bps y/y -3% y/y $234M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI: +3% | M&A: 0% | FX: +1% 59.6% | -180bps y/y 19.1% 90% Adj. Net Interest & Other: $20M Reconciliati
Slide 6: Life Sciences
Life Sciences LIFE SCIENCE SOLUTIONS SOFTWARE REVENUE AJUSTED OP MARGINS +DD 4% Organic Growth 31.6% Reported: 5% | M&A: 0% | FX: +1% -220bps y/y $366 M • +MSD growth from Pharma/Biotech, -LSD decline from 2Q25 revenue Academic/Gov’t -LSD • -LSD decline in Life Science Solutions; instrument declines
Slide 7: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE REVENUE AJUSTED OP MARGINS HEALTH 2% Organic Growth 25.2% Reported: 3% | M&A: 0% | FX: +1% -180 bps y/y +LSD $354 M • +LSD ImmunoDX globally; -DD in China +LSD 2Q25 revenue • +LSD Reproductive Health globally driven by strength in newborn • Margin pressure
Slide 8: 2025 Financial Guidance
2025 Financial Guidance REVENUE $2.84B - $2.88B Reported: 3% to 5% Organic: 2% to 4% FX: 1%, M&A: 0% ADJUSTED OP. MARGIN 27.1-27.3% ADJUSTED EPS $4.85 - $4.95 Adj. Net interest expense, other: ~$80M Adjusted tax rate: ~18% Average diluted share count: ~117M 8
Slide 9: Revvity.com
Revvity.com